Nilotinib as first-line therapy for chronic myeloid leukemia.
Loading...
Date
2011-10
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Tyrosine Kinase Inhibitors brought a revolution in the management of chronic myeloid leukemia. Long term disease free survival became a reality for the majority of patients. With the identification of imatinib resistance and its implications, roles of newer targeted therapy molecules came into focus. Nilotinib data has matured and shows the fulfillment of earlier promise - even in first line therapy. This review provides insight into the place of this molecule in the first line management of chronic myeloid leukemia.
Description
Keywords
Tyrosine kinase inhibitor, response, safety, overcoming resistance
Citation
Vaid A. Nilotinib as first-line therapy for chronic myeloid leukemia. Indian Journal of Cancer. 2011 Oct-Dec; 48(4): 438-445.